|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Temsimlimus, interferon alfa, or both for advanced renal-cell carcinoma显示文摘 | Hudes G Cardueci M Tomczak P | 2007 | N Engl J Med2007，356，： | 1 |
| 2 | Phase Ⅰ study of paclitaxel and estramustine:preliminary activity in hormone-refractory prostate cancer显示文摘 | Hudes G R Obasaju C Chapman A | 1995 | Semin Oncol1995，22，： | 1 |
| 3 | Temsirolimus,Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma 显示文摘 | Hudes G Carducci M Tomczak P | 2007 | N Engl J Med2007，356，22： | 1 |
| 4 | Phase Ⅱ trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer显示文摘 | Hudes G R Nathan F Khater C | 1997 | J Clin Oncol1997，15，： | 1 |
| 5 | Temsi- rolimus, interferon alfa, or both for advanced renal-cell carcinoma显示文摘 | HUDES G CARDUCCI M TOMCZAK P | 2007 | N Engl J Med2007，356，22： | 1 |
| 6 | Phase I1 study of axitinib in sorafenib-reffactory metastatic renal cell carcinoma 显示文摘 | Rini BI Wilding G Hudes G | 2009 | J Clin Oncol2009，27，27： | 1 |
| 7 | Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma 显示文摘 | Hudes G Carducci M Tomczak P | 2007 | NEnglJMed2007，356，22： | 1 |
| 8 | Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma显示文摘 | HUDES G CARDUCCI M TOMCZAK P | 2007 | N Engl J Med2007，356，22： | 1 |
| 9 | Antioxidant supplementation decreases lipid peroxidation biomarker F (2)-isoprostanes in plasma of smokers显示文摘 | Dietrich M Block G Hudes M | | 0，，01： | 1 |
| 10 | Targeting mTOR in renal cell carcinoma显示文摘 | HUDES G R | 2009 | Cancer2009，115，10： | 1 |
| 11 | Temsirolimus,interferon alfa,or both for advanced renal-cell carcinoma显示文摘 | Hudes G Carducci M Tomczak P | | 0，，22： | 1 |
| 12 | Temsirolimus,interfer-on alfa,or both for advanced renal-cell carcinoma 显示文摘 | Hudes G Carducci M Tomczak P | 2007 | N Engl JMed2007，356，22： | 1 |
| 13 | Phase II study ofaxitinib in sorafenib - refactory metastatic reanl cell carcinoma 显示文摘 | Rini HI Wilding G Hudes G | 2009 | J Clin Oncol2009，27，27： | 1 |
| 14 | Temsirolimus, interferon alfa, or both for advanced renal-cell carci- noma显示文摘 | Hudes G Carducci M Tomczak P | 2007 | N Engl J Med2007，356，22： | 1 |
| 15 | Temsiroli-mus, interferon alfa, or both for advanced renal-cell carcinoma 显示文摘 | HUDES G CARDUCCI M TOMCZAK P | 2007 | N Engl J Med2007，356，22： | 1 |
| 16 | A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interfemn--a(IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor risk patients with ad- vanced renal cell carcinoma ( adv RCC ) 显示文摘 | HUDES G CARDUCCI M TOMCZAK P | 2006 | Pmc Am Soc Clin Onco12006，24，： | 1 |
| 17 | Axitinib ( AG- 013736; AG) in patients with metastatic renal cell cancer (RCC) refractory to sorafenib 显示文摘 | Rini BI Wilding GT Hudes G | 2007 | J Clin Oncol (Meeting Abstracts)2007，25，18： | 1 |
| 18 | Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma 显示文摘 | Hudes G Carducci M Tomczak P | 2007 | N Engl J Med2007，356，22： | 1 |
| 19 | Sequential axi- tinib (AG-013736) therapy of patients (pts) with metastatie clear cell renal cell eaneer (RCC) refractory to sunitinib and sorafenib, eytokines and sorafenib, or sorafenib alone 显示文摘 | DUTCHER JP WILDING G HUDES GR | 2008 | J Clin Oneol2008，26，15： | 1 |
| 20 | Temsirolimus, inter- feron alfa, or both for advanced renal-cell carcinoma 显示文摘 | Hudes G Carducci M Tomczark P | 2007 | New Engl J Med2007，356，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员